Amgen Will Use Onyx To Carry Out Blincyto Launch
The big biotech is prepared to launch its newly approved leukemia drug blinatumomab through its Onyx subsidiary in a matter of weeks, despite the rapid approval timeline.
The big biotech is prepared to launch its newly approved leukemia drug blinatumomab through its Onyx subsidiary in a matter of weeks, despite the rapid approval timeline.